Charles Schwab Investment Management Inc. Has $2.99 Billion Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Charles Schwab Investment Management Inc. decreased its position in Amgen Inc. (NASDAQ:AMGN) by 4.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,393,110 shares of the medical research company’s stock after selling 500,785 shares during the period. Amgen comprises approximately 0.8% of Charles Schwab Investment Management Inc.’s holdings, making the stock its 22nd largest holding. Charles Schwab Investment Management Inc. owned 1.94% of Amgen worth $2,993,424,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. OFI Invest Asset Management acquired a new position in shares of Amgen in the 3rd quarter worth approximately $26,000. Briaud Financial Planning Inc bought a new position in shares of Amgen in the 3rd quarter worth $26,000. BOK Financial Private Wealth Inc. bought a new position in shares of Amgen in the 4th quarter worth $29,000. Providence Capital Advisors LLC acquired a new stake in Amgen during the 3rd quarter worth $30,000. Finally, Planned Solutions Inc. acquired a new stake in shares of Amgen in the 4th quarter valued at about $30,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ:AMGN traded up $3.87 on Wednesday, reaching $304.17. The company’s stock had a trading volume of 1,126,768 shares, compared to its average volume of 2,889,406. The company has a 50-day simple moving average of $275.65 and a 200 day simple moving average of $281.74. The company has a market cap of $163.15 billion, a P/E ratio of 43.44, a PEG ratio of 3.00 and a beta of 0.60. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. The company had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The firm’s revenue for the quarter was up 22.0% on a year-over-year basis. During the same quarter last year, the business posted $3.98 EPS. As a group, equities research analysts anticipate that Amgen Inc. will post 19.46 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 2.96%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is presently 128.57%.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of Amgen stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the sale, the senior vice president now directly owns 9,883 shares in the company, valued at approximately $3,094,268.47. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.69% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms recently issued reports on AMGN. Royal Bank of Canada lowered their target price on Amgen from $332.00 to $328.00 and set an “outperform” rating on the stock in a research report on Friday, May 3rd. TD Cowen reduced their price target on Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a report on Wednesday, April 17th. Morgan Stanley boosted their price objective on Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a report on Friday, May 3rd. Barclays upgraded shares of Amgen from an “underweight” rating to an “equal weight” rating and lifted their price target for the company from $230.00 to $300.00 in a research report on Friday, May 3rd. Finally, William Blair upgraded shares of Amgen from a “market perform” rating to an “outperform” rating in a research report on Friday, May 3rd. Ten research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $305.05.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.